Publications

Results from the Phase 2 Trial of Ridaforolimus, Dalotuzumab, and Exemestane Compared to Ridaforolimus and Exemestane in Advanced Breast Cancer

AuthID
P-00G-D2S

Author(s)

Rugo, HS

Tredan, O

Ro, J

Morales, S

Musolino, A

Afonso, N

Ferreira, M

Park, KH

Cortes, J

Tan, AR

Blum, JL

Eaton, L

Gause, CK

Wang, A

Im, E

Mauro, DJ

Baselga, J

Document Type

Abstract

Year published

2015

Published

in CANCER RESEARCH, ISSN: 0008-5472

Volume: 75, Issue: 9, Pages: PD5-1-PD5-1 (2)

Conference

37Th Annual Ctrc-Aacr San Antonio Breast Cancer Symposium, Date: DEC 09-13, 2014, Location: San Antonio, TX, Sponsors: CTRC, AACR

Indexing

Wos^®

Crossref^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1158/1538-7445.sabcs14-pd5-1

Wos: WOS:000356730200165

Source Identifiers

ISSN: 0008-5472

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Results from the Phase 2 Trial of Ridaforolimus, Dalotuzumab, and Exemestane Compared to Ridaforolimus and Exemestane in Advanced Breast Cancer

Useful Links

Get Help

Federated Authentication (Click on the image)

Results from the Phase 2 Trial of Ridaforolimus, Dalotuzumab, and Exemestane Compared to Ridaforolimus and Exemestane in Advanced Breast Cancer

Useful Links

Get Help